Position in EXEL
as of Mar 31, 2026
· filed May 21, 2026
Position Value
$537,283
-$529,802 QoQ
Shares Held
12,527
-48.5% QoQ
Ownership
0.005%
of shares outstanding
% of Portfolio
0.22%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Essential Partners LLC holds $6,271,326 across 179 Biotechnology names. EXEL ranks #3 (8.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
28,674 | $2,698,796 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
735 | $567,890 | |
| 3 | EXEL |
Exelixis, Inc.
This page
|
12,527 | $537,283 | |
| 4 | BMRN |
Biomarin Pharmaceutical Inc
|
8,777 | $495,812 | |
| 5 | GLUE |
Monte Rosa Therapeutics, Inc.
|
13,028 | $214,310 | |
| 6 | PTCT |
Ptc Therapeutics, Inc.
|
2,369 | $161,399 | |
| 7 | SRPT |
Sarepta Therapeutics, Inc.
|
5,784 | $125,859 | |
| 8 | FTRE |
Fortrea Holdings Inc.
|
9,675 | $91,138 |
All Filings in EXEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $537,283 | 12,527 | Shares | Sole | 2026-05-21 | |
| 2025-12-31 | $1,067,085 | 24,346 | Shares | Sole | 2026-05-21 | |
| 2025-09-30 | $730,349 | 17,684 | Shares | Sole | 2026-05-21 | |
| 2025-06-30 | $710,525 | 16,119 | Shares | Sole | 2026-05-21 | |
| No filing history on record for this holder in this stock. | ||||||